Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results)
Yazar
Buffels, R.
Comi, G.
Wiendl, H.
Kuhelj, R.
Wei, W.
Siva, A.
Vermersch, P.
Eralinna, J. -P.
Nicholas, R.
Oreja-Guevara, C.
Van Wijmeersch, B.
Üst veri
Tüm öğe kaydını gösterKoleksiyonlar
- Bildiri [64839]